Expertise in
16
conditions

Dr. Salma K. Jabbour

Radiation Oncology
Surgical Oncology Associates/BHMG
195 Little Albany St, 
New Brunswick, NJ 
Accepting New Patients
Expertise in
16
conditions
Surgical Oncology Associates/BHMG
195 Little Albany St, 
New Brunswick, NJ 

Overview

Salma Jabbour is a Radiation Oncologist practicing medicine in New Brunswick, New Jersey.

Dr. Jabbour is highly rated in 16 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pancreaticoduodenectomy, and Liver Embolization.

She is actively involved in clinical research, co-authoring 239 peer reviewed articles and participating in 19 clinical trials. Dr. Jabbour is currently accepting new patients.

Specialties

Radiation Oncology

Licenses

Radiology in NJ

Hospital Affiliations

Robert Wood Johnson University Hospital - Somerset
Robert Wood Johnson University Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Surgical Oncology Associates/BHMG
195 Little Albany St, New Brunswick, NJ 08901

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Carboplatin, Ipilimumab, Nivolumab, Paclitaxel
Study Phase: Phase 2/Phase 3
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: August 21, 2026
Intervention Type: Drug, Radiation, Procedure
Study Drugs: Avelumab, Peposertib
Study Phase: Phase 1/Phase 2
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Phase II Trial of Radium-223 Dichloride in Combination With Paclitaxel in Patients With Bone Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Procedure, Other, Radiation, Drug
Study Drug: Paclitaxel
Study Phase: Phase 2
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
A Phase 2 Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Radiation
Study Drugs: Durvalumab, Tremelimumab
Study Phase: Phase 2
The Role of Adaptive Radiation Planning in Patients With Non-Small Cell Lung Cancer on Radiation Induced Toxicity
The Role of Adaptive Radiation Planning in Patients With Non-Small Cell Lung Cancer on Radiation Induced Toxicity
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Other
Study Phase: Not Applicable
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: January 28, 2026
Intervention Type: Radiation, Drug
Study Drug: Sorafenib Tosylate
Study Phase: Phase 3
View 9 Less Clinical Trials

239 Total Publications

Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.
Comprehensive Patient Reported Outcomes (PROs) from NRG Oncology/Alliance LU005: A Randomized Trial Of Chemoradiation +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: June 09, 2026
Similar Doctors
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Expertise in
17
conditions
Dr. Andreas Rimner
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (31.8 miles away)
212-639-2000
Languages Spoken:
English

Andreas Rimner is a Radiation Oncologist practicing medicine in New York, New York. Dr. Rimner is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, Tissue Biopsy, and Thymectomy.

Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Expertise in
54
conditions
Dr. Kaled M. Alektiar
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (31.8 miles away)
646-582-9491
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kaled Alektiar is a Radiation Oncologist practicing medicine in New York, New York. Dr. Alektiar is highly rated in 54 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Adult Soft Tissue Sarcoma, Fibrosarcoma, Cervical Cancer, and Lymphadenectomy. Dr. Alektiar is currently accepting new patients.

Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Expertise in
17
conditions
Dr. Joachim Yahalom
Radiation Oncology
Referral may be required

Memorial Sloan Kettering Cancer Center

1275 York Ave, 
New York, NY 
 (31.8 miles away)
929-459-8263
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joachim Yahalom is a Radiation Oncologist practicing medicine in New York, New York. Dr. Yahalom is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma (MZL), Plasmacytoma, and Tissue Biopsy. Dr. Yahalom is currently accepting new patients.

Frequently Asked Questions about Dr. Salma K. Jabbour

How do I make an appointment with Dr. Salma K. Jabbour?

You can book an appointment with Dr. Salma K. Jabbour by calling their office at 973-891-9392. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Salma K. Jabbour a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Salma K. Jabbour is classified as an Elite expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Salma K. Jabbour specialize in?

While Dr. Salma K. Jabbour is a Radiation Oncology, they have specific expertise in Lung Cancer, Small Cell Lung Cancer (SCLC), and Non-Small Cell Lung Cancer (NSCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Salma K. Jabbour participate in research or clinical trials?

Yes. Dr. Salma K. Jabbour has published 239 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Salma K. Jabbour's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Salma K. Jabbour accept my insurance?

Dr. Salma K. Jabbour accepts most major insurance plans, including Aetna and Cigna. We recommend calling the office directly at 973-891-9392 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jabbour's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 46 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile